Company Description
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria.
The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
| Country | United States |
| IPO Date | May 4, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 135 |
| CEO | Mina Kim J.D. |
Contact Details
Address: 4149 Liberty Canyon Road Agoura Hills, California United States | |
| Website | https://www.acelyrin.com |
Stock Details
| Ticker Symbol | SLRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001962918 |
| CUSIP Number | 00445A100 |
| ISIN Number | US00445A1007 |
| Employer ID | 85-2406735 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mina Kim J.D. | Chief Executive Officer & Director |
| Gilbert M. Labrucherie J.D. | Chief Financial Officer & Chief Business Officer |
| K. Amar Murugan J.D. | Chief Legal Officer |
| Kelly Chow | Chief People Officer |
| Dr. Shephard Mpofu M.D. | Chief Medical Officer |
| Kenneth A. Lock | Chief Commercial Officer |
| Patricia A. Turney | Chief Technical Operations Officer |
| Suzy Buckhalter CPA | Senior Director of Finance & Accounting |
| Tyler Marciniak | Head of Investor Relations & Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 4 | Filing |
| Nov 22, 2024 | 3 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | S-3 | Filing |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |